RxDoctor Payments Data

Mary Tyson, MD

Psychiatry · Augusta, GANPI 1780669218

Payments from drug & device makers

$16,572in general payments, 2019–2025

Across 796 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • Alkermes, Inc.$3K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • plus $4K from 8 others

What the payments were for

  • Food & beverage$16,05297%
  • Education$5213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,572 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$16,223
Medicare patients
66
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine74$565,592
CaplytaLumateperone Tosylate156$271,064
AristadaAripiprazole Lauroxil79$219,132
Invega SustennaPaliperidone Palmitate63$217,571
Invega TrinzaPaliperidone Palmitate29$210,983
Austedo XrDeutetrabenazine20$129,272
Abilify MaintenaAripiprazole41$118,320
UzedyRisperidone29$107,217
VraylarCariprazine Hcl68$106,179
Abilify AsimtufiiAripiprazole15$84,091
LybalviOlanzapine/Samidorphan Malate31$50,149
Lurasidone Hcl137$43,854
Clozapine218$23,091
RexultiBrexpiprazole14$20,890
AuvelityDextromethorphan Hbr/Bupropion21$19,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy$3,231$802,081123 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$2,117$428,55492 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,372$271,064156 claims
Alkermes, Inc.Aristada, Lybalvi$2,829$269,281110 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti$1,332$223,30170 claims
AbbVieVraylar$1,589$106,17968 claims
Axsome Therapeutics, Inc.Auvelity$304$19,73621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →